[1]Patent:US2006/63926,2006,A1,.Locationinpatent:Page/Pagecolumn6;11
[1]Patent:WO2018/140377,2018,A1,.Locationinpatent:Paragraph00325;00327
[1]ACSChemicalNeuroscience,2018,vol.9,#6,p.1259-1263
[1]OrganicProcessResearchandDevelopment,2012,vol.16,#12,p.1897-1904
[1]Patent:US6495541,2002,B1,
[1]Patent:WO2004/87713,2004,A1.Locationinpatent:Page10
[2]Patent:WO2019/86509,2019,A1.Locationinpatent:Page/Pagecolumn17
[1]Patent:CN109824677,2019,A.Locationinpatent:Paragraph0043
[2]Patent:US2006/63926,2006,A1.Locationinpatent:Page/Pagecolumn6;11
[1]Patent:US6495541,2002,B1
283173-50-2
[1]Patent:WO2006/33007,2006,A2.Locationinpatent:Page/Pagecolumn27-28
110-16-7
[1]Patent:WO2011/98971,2011,A1.Locationinpatent:Page/Pagecolumn81
Title: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England) 20171028
Title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Journal: The Lancet. Oncology 20170101
Title: Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
Journal: Future oncology (London, England) 20160601
Title: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Journal: British journal of cancer 20160329
Title: An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Journal: BMC cancer 20160101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Journal: Cancer discovery 20120901
Title: Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Journal: Nature medicine 20110701
Title: Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
Journal: British journal of cancer 20101109
Title: Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100415
Title: Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
Journal: Cancer journal (Sudbury, Mass.) 20100101
Title: Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
Journal: Breast cancer research : BCR 20100101
Title: Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091001
Title: Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
Title: Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081201
Title: Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Journal: Molecular cancer therapeutics 20070301
Title: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Journal: Journal of the National Cancer Institute 20040107
Title: Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20000701
Title: Thomas HD, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther, 2007, 6(3), 945-956.
Title: J Murray, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014 Apr 15;110(8):1977-84.
Title: Daniel RA, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res, 2009, 15(4), 1241-1249.
Title: Jianneng Li, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Sci Transl Med. 2021 May 26;13(595):eabe8226.
Title: Hunter JE, et al. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene, 2012, 31(2), 251-264.
Title: Matt Shirley, et al. Rucaparib: A Review in Ovarian Cancer. Target Oncol. 2019 Apr;14(2):237-246.
